摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Nα-isobutyl-Nα-(4-acetamidobenzenesulfonyl)-L-α-ε-amino-caprolactam | 449806-97-7

中文名称
——
中文别名
——
英文名称
Nα-isobutyl-Nα-(4-acetamidobenzenesulfonyl)-L-α-ε-amino-caprolactam
英文别名
Nα-isobutyl-Nα-(4-acetamidobenzenesulfonyl)-L-α-amino-ε-caprolactam;Nα-isobutyl-Nα-(4-acetamido-benzenesulfonyl)-α-amino-L-caprolactam;Nα-isobutyl-Nα-(4-acetamidobenzenesulfonyl)-L-α-amino-caprolactam;N-[4-[2-methylpropyl-[(3S)-2-oxoazepan-3-yl]sulfamoyl]phenyl]acetamide
Nα-isobutyl-Nα-(4-acetamidobenzenesulfonyl)-L-α-ε-amino-caprolactam化学式
CAS
449806-97-7
化学式
C18H27N3O4S
mdl
——
分子量
381.496
InChiKey
MYMIXTCBZKOMJU-KRWDZBQOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    230-233 °C(Solv: ethanol (64-17-5))
  • 密度:
    1.25±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    104
  • 氢给体数:
    2
  • 氢受体数:
    5

SDS

SDS:4d6623d385b34d6a86fff45e03bfe04a
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas
    摘要:
    A series of lysine sulfonamide analogues bearing a Nepsilon-benzylic ureas was synthesized using both solution-phase and solid-phase approaches. A novel synthetic route of Nalpha-(alkyl)-Nalpha-(sulfonamides)lysinol using alpha-amino-caprolactam was developed. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type HIV virus. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.05.049
  • 作为产物:
    参考文献:
    名称:
    Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas
    摘要:
    A series of lysine sulfonamide analogues bearing a Nepsilon-benzylic ureas was synthesized using both solution-phase and solid-phase approaches. A novel synthetic route of Nalpha-(alkyl)-Nalpha-(sulfonamides)lysinol using alpha-amino-caprolactam was developed. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type HIV virus. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.05.049
点击查看最新优质反应信息

文献信息

  • Lysine based compounds
    申请人:Stranix Richard Brent
    公开号:US20060025592A1
    公开(公告)日:2006-02-02
    The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R 1 may be, for example, (HO) 2 P(O)—, (NaO) 2 P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R 2 and R 3 are as defined herein.
    本发明提供了一种式I的赖氨酸基化合物;当式I的化合物包含氨基时,还包括其药学上可接受的铵盐,其中R1可以是例如(HO)2P(O)—、(NaO)2P(O)—、烷基-CO—或环烷基-CO—,其中X可以是例如F、Cl和Br,而R2和R3如本文所定义。
  • [EN] LYSINE BASED COMPOUNDS<br/>[FR] COMPOSES A BASE DE LYSINE
    申请人:PROCYON BIOPHARMA INC
    公开号:WO2006012725A1
    公开(公告)日:2006-02-09
    The present invention provides lysine based compounds of the formula (I); and when the compound of formula (I) comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein Rl may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkyl­CO- or cycloalkyl-CO-, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein. These lysine based compounds have a physiologically cleavable unit, namely R1 , whereby upon cleavage of the unit, an HIV aspartyl protease inhibitor is released,
    本发明提供了以赖氨酸为基础的化合物的公式(I);当公式(I)的化合物包含氨基时,其药用可接受的铵盐,其中R1可以是,例如,(HO)2P(O)-,(NaO)2P(O)-,烷基CO-或环烷基CO-,其中X可以是,例如,F,Cl和Br,而R2和R3如本文所定义。这些以赖氨酸为基础的化合物具有一个生理可切割的单元,即R1,通过切割该单元,释放出HIV天冬氨酸蛋白酶抑制剂。
  • Aromatic derivatives as HIV aspartyl protease inhibitors
    申请人:Pharmacor Inc.
    公开号:US06632816B1
    公开(公告)日:2003-10-14
    The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be, for example, iso-butyl, wherein X and Y, same or different, may be, for example, NH2 and F, and wherein R2 and R3 are as defined herein.
    本发明提供了化学式为的HIV天冬氨酸蛋白酶抑制剂;当化合物的化学式I包含氨基时,其药学上可接受的铵盐,其中n为3或4,其中R1可能是,例如,异丁基,其中X和Y,相同或不同,可能是,例如,NH2和F,其中R2和R3如本文所定义。
  • Protease Inhibitors
    申请人:Stranix Brent Richard
    公开号:US20100184974A1
    公开(公告)日:2010-07-22
    The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R 2 may be, for example, 2-pyridyl-CH 2 —, 3-pyridyl-CH 2 —, 4-pyridyl-CH 2 —, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R 2a —CO)—, R 2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR 5 R 6 , CH 2 OH or CH 2 OR 7 .
    本发明提供了公式I、IA、IB、Ib或II的HIV蛋白酶抑制剂,或其药学上可接受的盐,其中R2可能是,例如,2-吡啶基-CH2—,3-吡啶基-CH2—,4-吡啶基-CH2—,如本文中所述的磺酰基,包括苯磺酰基或噻吩磺酰基,R2a—CO)—,R2a选自由本文中所述的吡哌啶基、2-吡啶基(未取代或取代为H,或1至4个碳原子的烷基)或本文中所述的吡哌啶胺基,其中R3可能是,例如,本文中所述的苯基或二苯甲基基团,Cx可能是,例如,COOH、CONR5R6、CH2OH或CH2OR7。
  • Urea derivatives as HIV aspartyl protease inhibitors
    申请人:Pharmacor Inc.
    公开号:US06528532B1
    公开(公告)日:2003-03-04
    The present invention provides HIV aspartyl protease inhibitors of the formula: and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, Y is O, S, NH or N—CN, wherein Cx may be, for example COOH, or CH2OH, wherein R1 is selected from the group consisting of a benzenesulfonyl group of formula II as defined herein, wherein R2 may be, for example, iso-butyl, or 3-methylbutyl, and wherein R3 and R4 are as defined herein.
    本发明提供了HIV天冬氨酸蛋白酶抑制剂的化学式:当化合物I的化学式包括氨基时,其药用可接受的铵盐,其中n为3或4,Y为O、S、NH或N—CN,其中Cx可以是例如COOH或CH2OH,其中R1选自所述的苯甲磺酰基II的群,其中R2可以是例如异丁基或3-甲基丁基,R3和R4的定义如本文所述。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐